Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?
About
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Resolution
Criteria
Resolves YES based on the official Polymarket resolution for: "Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?"
Context
The FDA's Bulk Drug Substances List categorizes substances based on their regulatory status, with Category 1 indicating the substance is approved for use in a pharmaceutical product. Historically, reclassification of substances on this list has been influenced by emerging scientific evidence and regulatory reviews. To determine the outcome of BPC-157's potential reclassification, it is essential to monitor FDA announcements and updates on the bulk drug substances list, as well as any developments in the scientific understanding of BPC-157's safety and efficacy.
Recent News
The FDA is taking steps towards reclassifying certain peptides, including BPC-157, which could potentially ease restrictions on their use, although significant regulatory hurdles must still be cleared. A formal plan for reclassification, announced by RFK Jr., is set to take effect in 2026, pending further FDA action and approval.
- The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means - Pharmacy Times
Pharmacy Times
- Peptides Aren't Actually Legal Yet, Here's What Has to Happen Before RFK Jr.'s 2026 Plan Takes Effect - Raleigh News & Observer
Raleigh News & Observer
- FDA moves toward easing restrictions on certain peptides - BioPharma Dive
BioPharma Dive
Discussion
Sign in to join the discussion.